News >

Pembrolizumab Investigated as Adjuvant RCC Therapy

Angelica Welch
Published: Monday, Dec 18, 2017

Tian Zhang, MD

Tian Zhang, MD
Immunotherapy has had a major impact on the treatment landscape of renal cell carcinoma (RCC) in 2017. With the intriguing findings of the phase III CheckMate-214 trial, physicians are apt to investigate immunotherapy agents in different settings of this disease.

KEYNOTE-564 lead investigator Tian Zhang, MD, assistant professor of medicine, Duke University School of Medicine, Duke Cancer Institute, discussed this phase III study, as well as the progress that immunotherapy has made in the treatment paradigm of patients with RCC.

OncLive: Please provide an overview of the KEYNOTE-564 trial.

Zhang: This is a trial in progress of an adjuvant [therapy] in RCC. We just started accruing patients earlier this year. This study is one of a few aimed at improving adjuvant treatment for [patients with] kidney cancer. The study randomizes patients to either pembrolizumab alone or placebo.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x